Rationale, design and methodology of APPROACH-IS II: International study of patient-reported outcomes and frailty phenotyping in adults with congenital heart disease.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 09 2022
Historique:
received: 20 04 2022
revised: 22 06 2022
accepted: 27 06 2022
pubmed: 6 7 2022
medline: 20 7 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

In recent years, patient-reported outcomes (PROs) have received increasing prominence in cardiovascular research and clinical care. An understanding of the variability and global experience of PROs in adults with congenital heart disease (CHD), however, is still lacking. Moreover, information on epidemiological characteristics and the frailty phenotype of older adults with CHD is minimal. The APPROACH-IS II study was established to address these knowledge gaps. This paper presents the design and methodology of APPROACH-IS II. APPROACH-IS II is a cross-sectional global multicentric study that includes Part 1 (assessing PROs) and Part 2 (investigating the frailty phenotype of older adults). With 53 participating centers, located in 32 countries across six continents, the aim is to enroll 8000 patients with CHD. In Part 1, self-report surveys are used to collect data on PROs (e.g., quality of life, perceived health, depressive symptoms, autonomy support), and explanatory variables (e.g., social support, stigma, illness identity, empowerment). In Part 2, the cognitive functioning and frailty phenotype of older adults are measured using validated assessments. APPROACH-IS II will generate a rich dataset representing the international experience of individuals in adult CHD care. The results of this project will provide a global view of PROs and the frailty phenotype of adults with CHD and will thereby address important knowledge gaps. Undoubtedly, the project will contribute to the overarching aim of improving optimal living and care provision for adults with CHD.

Sections du résumé

BACKGROUND
In recent years, patient-reported outcomes (PROs) have received increasing prominence in cardiovascular research and clinical care. An understanding of the variability and global experience of PROs in adults with congenital heart disease (CHD), however, is still lacking. Moreover, information on epidemiological characteristics and the frailty phenotype of older adults with CHD is minimal. The APPROACH-IS II study was established to address these knowledge gaps. This paper presents the design and methodology of APPROACH-IS II.
METHODS/DESIGN
APPROACH-IS II is a cross-sectional global multicentric study that includes Part 1 (assessing PROs) and Part 2 (investigating the frailty phenotype of older adults). With 53 participating centers, located in 32 countries across six continents, the aim is to enroll 8000 patients with CHD. In Part 1, self-report surveys are used to collect data on PROs (e.g., quality of life, perceived health, depressive symptoms, autonomy support), and explanatory variables (e.g., social support, stigma, illness identity, empowerment). In Part 2, the cognitive functioning and frailty phenotype of older adults are measured using validated assessments.
DISCUSSION
APPROACH-IS II will generate a rich dataset representing the international experience of individuals in adult CHD care. The results of this project will provide a global view of PROs and the frailty phenotype of adults with CHD and will thereby address important knowledge gaps. Undoubtedly, the project will contribute to the overarching aim of improving optimal living and care provision for adults with CHD.

Identifiants

pubmed: 35780933
pii: S0167-5273(22)01018-X
doi: 10.1016/j.ijcard.2022.06.064
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-39

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Liesbet Van Bulck (L)

KU Leuven - University of Leuven, Leuven, Belgium; Research Foundation Flanders (FWO), Brussels, Belgium.

Adrienne H Kovacs (AH)

Oregon Health & Science University, Portland, OR, USA.

Eva Goossens (E)

KU Leuven - University of Leuven, Leuven, Belgium; University of Antwerp, Antwerp, Belgium.

Koen Luyckx (K)

KU Leuven - University of Leuven, Leuven, Belgium; UNIBS, University of the Free State, Bloemfontein, South Africa.

Ali Zaidi (A)

Mount Sinai Heart, New York, NY, USA.

Jou-Kou Wang (JK)

National Taiwan University Hospital, Taipei City, Taiwan.

Dejuma Yadeta (D)

Addis Ababa University, Addis Ababa, Ethiopia.

Jonathan Windram (J)

Mazankowski Alberta Heart Institute, Edmonton, Canada.

Alexander Van De Bruaene (A)

University Hospitals Leuven, Leuven, Belgium.

Corina Thomet (C)

Inselspital, Bern University Hospital, University of Bern, Switzerland.

Jean-Benoît Thambo (JB)

Hôpital cardiologique Haut-Leveque, Bordeaux, France.

Marshall Taunton (M)

Oregon Health & Science University, Portland, OR, USA.

Navaneetha Sasikumar (N)

Amrita Institute of Medical Sciences, Kochi, Kerala, India.

Camilla Sandberg (C)

Umeå University, Umeå, Sweden.

Arwa Saidi (A)

University of Florida Health, Gainesville, FL, USA.

Tobias Rutz (T)

Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Lucia Ortiz (L)

Hospital San Juan De Dios De La Plata, Buenos Aires, Argentina.

Julius Chacha Mwita (JC)

University of Botswana and Princess Marina Hospital, Gaborone, Botswana.

Ju Ryoung Moon (JR)

Samsung Medical Center, Seoul, South Korea.

Samuel Menahem (S)

Monash University, Melbourne, Australia.

Eva Mattsson (E)

Karolinska Institutet, Stockholm, Sweden.

Zacharias Mandalenakis (Z)

Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.

Vaikom S Mahadevan (VS)

University of California San Francisco (UCSF), San Francisco, CA, USA.

Birgitte Lykkeberg (B)

Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Mohamed Leye (M)

University of Thiés, Thiés, Senegal.

Ming Chern Leong (MC)

IJN (National Heart Institute), Kuala Lumpur, Malaysia.

Magalie Ladouceur (M)

Hôpital Européen Georges Pompidou, AP-HP Paris, France.

Laila Akbar Ladak (LA)

Aga Khan University, Karachi, Pakistan.

Yuli Kim (Y)

Penn Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Paul Khairy (P)

Montreal Heart Institute, Université de Montréal, Montreal, Canada.

Anna Kaneva (A)

National Heart Hospital, Sofia, Bulgaria.

Bengt Johansson (B)

Umeå University, Umeå, Sweden.

Jamie L Jackson (JL)

Nationwide Children's Hospital, Columbus, OH, USA.

George Giannakoulas (G)

AHEPA University Hospital, Aristotle University of Thessaloniki, Greece.

Harald Gabriel (H)

Medical University of Vienna, Vienna, Austria.

Susan M Fernandes (SM)

Lucile Packard Children's Hospital and Stanford Health Care, Stanford, CA, USA.

Junko Enomoto (J)

Chiba Cerebral and Cardiovascular Center, Chiba, Japan; Toyo University, Tokyo, Japan.

Fatma Demir (F)

Ege University Health Application and Research Center, Bornova/İZMİR, Turkey.

Michèle de Hosson (M)

Ghent University Hospital, Ghent, Belgium.

Andrew Constantine (A)

Royal Brompton Hospital, Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Louise Coats (L)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Christina Christersson (C)

Uppsala University, Uppsala, Sweden.

Ari Cedars (A)

University of Southwestern Medical Center, TX, Dallas, USA; Johns Hopkins Hospital, Baltimore, MD, USA.

Maryanne Caruana (M)

Mater Dei Hospital, L-Imsida, Malta.

Edward Callus (E)

IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; University of Milan, Milan, Italy.

Sarah Brainard (S)

Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Judith Bouchardy (J)

Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Hôpitaux Universitaires de Genève, Genève, Switzerland.

Anna Boer (A)

University Medical Center Groningen, Groningen, the Netherlands.

Fernando Baraona Reyes (F)

Pontificia Universidad Católica de Chile and Instituto Nacional Del Torax, Santiago, Chile.

Maria Emília Areias (ME)

UnIC@RISE, University of Porto, Porto, Portugal; Centro Hospitalar Universitário de S. João, Porto, Portugal.

John Jairo Araujo (JJ)

Meintegral-Clinic, Manizales, Colombia.

Brith Andresen (B)

Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Pascal Amedro (P)

Hôpital cardiologique Haut-Leveque, Bordeaux, France; Montpellier University Hospital, Montpellier, France.

Jean-Claude Ambassa (JC)

Clinique Medical Le Jourdain, Yaoundé, Cameroon.

Fernando Amaral (F)

University Hospital, Ribeirão Preto Medical School, Brazil.

Luis Alday (L)

Hospital de Niños, Cordoba, Argentina.

Philip Moons (P)

KU Leuven - University of Leuven, Leuven, Belgium; University of Gothenburg, Gothenburg, Sweden; University of Cape Town, Cape Town, South Africa. Electronic address: philip.moons@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH